Exenatide

Generic Name: exenatide

GLP-1 Receptor Agonist [EPC]Over-the-Counter (OTC)

Brand Names:

Exenatide

11 DESCRIPTION Exenatide is a synthetic peptide, GLP-1 receptor agonist, that was originally identified in the lizard Heloderma suspectum . Exenatide is a 39-amino acid peptide amide. Exenatide has the empirical formula C 184 H 282 N 50 O 60 S and molecular weight of 4186.6 Daltons. The amino acid sequence for exenatide is shown below.

Overview

11 DESCRIPTION Exenatide is a synthetic peptide, GLP-1 receptor agonist, that was originally identified in the lizard Heloderma suspectum . Exenatide is a 39-amino acid peptide amide. Exenatide has the empirical formula C 184 H 282 N 50 O 60 S and molecular weight of 4186.6 Daltons. The amino acid sequence for exenatide is shown below.

Uses

1 INDICATIONS AND USAGE Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.

Dosage

2 DOSAGE AND ADMINISTRATION Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). ( 2.1 ) Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response. ( 2.1 ) 2.1 Recommended Dosing Initiate exenatide injection at 5 mcg administered subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). Do not administer after a meal.

Side Effects

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Acute Pancreatitis [see Warnings and Precautions (5.1) ] Never Share an Exenatide Pen Between Patients [see Warnings and Precautions (5.2) ] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ] Immunogenicity [see Warnings and Precautions (5.6) ] Hypersensitivity [see Warnings and Precautions (5.7) ] Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ] Acute Gallbladder Disease [see Warnings and Precautions (5.9) ] Pulmonary Aspiration Dur...

Interactions

7 DRUG INTERACTIONS Table 6: Clinically Relevant Interactions with Exenatide Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . Intervention When initiating exenatide, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia. Warfarin Clinical Impact In a drug interaction study, exenatide did not have a significant effect on INR [see Clinical Pharmacology (12.3) ] .

Warnings

5 WARNINGS AND PRECAUTIONS Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including exenatide. Discontinue if pancreatitis is suspected. ( 5.1 ) Never share an exenatide injection pen between patients, even if the needle is changed. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may be necessary. ( 5.3 ) Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. 4 CONTRAINDICATIONS Exenatide injection is contraindicated in patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection [see Warnings and Precautions (5.7) ] .

Pregnancy

8.1 Pregnancy Risk Summary Limited data with exenatide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations) . Based on animal reproduction studies, there may be risks to the fetus from exposure to exenatide during pregnancy. Exenatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Storage

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Exenatide Injection, USP is supplied as a clear, colorless sterile solution for subcutaneous injection containing 250 mcg/mL exenatide, USP.

Frequently Asked Questions

What is Exenatide used for?

1 INDICATIONS AND USAGE Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.

What are the side effects of Exenatide?

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Acute Pancreatitis [see Warnings and Precautions (5.1) ] Never Share an Exenatide Pen Between Patients [see Warnings and Precautions (5.2) ] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ] Immunogenicity [see Warnings and Precautions (5.6) ] Hypersensitivity [see Warnings and Precautions (5.7) ] Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ] Acute Gallbladder Disease [see Warnings and Precautions (5.9) ] Pulmonary Aspiration Dur...

Can I take Exenatide during pregnancy?

8.1 Pregnancy Risk Summary Limited data with exenatide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations) . Based on animal reproduction studies, there may be risks to the fetus from exposure to exenatide during pregnancy. Exenatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

What are the important warnings for Exenatide?

5 WARNINGS AND PRECAUTIONS Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including exenatide. Discontinue if pancreatitis is suspected. ( 5.1 ) Never share an exenatide injection pen between patients, even if the needle is changed. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may be necessary. ( 5.3 ) Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. 4 CONTRAINDICATIONS Exenatide injection is contraindicated in patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection [see Warnings and Precautions (5.7) ] .

Related Medications

Fungal Nail Treatment Kit

fungal nail treatment kit

Purpose Antifungal

Aconitum Napellus, Argentum Nitricum, Arsenicum Album, Belladonna, Calcarea Carbonica, Carcinosin, Causticum, Gelsemium Sempervirens, Lachesis Mutus, Lithium Carbonicum, Lycopodium Clavatum, Mercurius Vivus, Nitricum Acidum, Phosphorus, Rhus Tox

aconitum napellus, argentum nitricum, arsenicum album, belladonna, calcarea carbonica, carcinosin, causticum, gelsemium sempervirens, lachesis mutus, lithium carbonicum, lycopodium clavatum, mercurius vivus, nitricum acidum, phosphorus, rhus tox

PURPOSE: Aconitum Napellus - panic,** Argentum Nitricum - anticipation,** Arsenicum Album - anguish,** Belladonna - nightmare,** Calcarea Carbonica - worry,** Carcinosin - sleeplessness,** Causticum - foreboding,** Gelsemium Sempervirens - dread,** Lachesis Mutus - suspicion,** Lithium Carbonicum - timidity,** Lycopodium Clavatum - cowardice,** Mercurius Vivus - nervousness,** Nitricum Acidum - hopelessness,** Phosphorus - fear,** Rhus Tox - restlessness.** **Claims based on traditional homeopat

Calcarea Carbonica, Calcarea Iodata, Ferrum Iodatum, Fucus Vesiculosus, Hepar Sulphuris Calcareum, Kali Iodatum, Lapis Albus Calcium Fluosilicate, Oryctolagus Cuniculus (rabbit) Adrenal Gland, Oryctolagus Cuniculus (rabbit) Pituitary Gland, Oryctolagus Cuniculus (rabbit) Spleen, Oryctolagus Cuniculus (rabbit) Thymus Gland, Oryctolagus Cuniculus (rabbit) Thyroid Gland, Spongia Tosta

calcarea carbonica, calcarea iodata, ferrum iodatum, fucus vesiculosus, hepar sulphuris calcareum, kali iodatum, lapis albus calcium fluosilicate, oryctolagus cuniculus (rabbit) adrenal gland, oryctolagus cuniculus (rabbit) pituitary gland, oryctolagus cuniculus (rabbit) spleen, oryctolagus cuniculus (rabbit) thymus gland, oryctolagus cuniculus (rabbit) thyroid gland, spongia tosta

Uses Helps promote and maintain normal metabolic functions.

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.